MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: Combined treatment with imatinib and trametinib, a MEK inhibitor, causes cell death, and prolongs survival in mouse models of BCR-ABL1-independent imatinib-resistant CML [26].